SCHEDULE: Soleus Capital Discloses 0.2% Stake in Terns Pharma
Beneficial Ownership Report
Soleus Capital entities and Guy Levy report beneficial ownership of 0.2% of Terns Pharmaceuticals, Inc. common stock.
Summary
- Soleus Capital Master Fund, L.P., along with related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 212,710 shares of Terns Pharmaceuticals, Inc. common stock.
- This aggregate amount represents 0.2% of the outstanding common stock of Terns Pharmaceuticals, Inc.
- The percentage is calculated based on 103,761,470 shares outstanding as of December 11, 2025, immediately following a public offering.
- All reporting persons share both voting and dispositive power over the 212,710 shares.
- The reporting persons disclaim beneficial ownership of these shares for any purpose other than determining their obligations under Section 13(d) of the Exchange Act.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance updates.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Soleus Capital Master Fund, L.P. directly holds the shares. Soleus Capital, LLC is the sole general partner of Master Fund. Soleus Capital Group, LLC is the sole managing member of Soleus Capital. Soleus Capital Management, L.P. is the investment manager for Master Fund. Soleus GP, LLC is the sole general partner of SCM. Guy Levy is the sole managing member of both SCG and Soleus GP, LLC, establishing a clear chain of control and related party relationships among the reporting entities and individual.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and significant holders, though the reported stake is relatively small (0.2%).
Key Dates
| Date | Description |
|---|---|
| 2025-12-09 | Date of prospectus supplement describing a public offering. |
| 2025-12-11 | Close of business date for 103,761,470 shares of common stock outstanding, immediately following the public offering. |
| 2025-12-31 | Date of event which requires filing of this statement. |
| 2026-02-12 | Signature date for the Schedule 13G filing. |
Keywords
Terns Pharmaceuticals, Soleus Capital, Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Institutional Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.